DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Managing Cancer and Living Meaningfully (CALM) Therapy in Individuals Diagnosed With a Primary Brain Tumor

Not Applicable

Completed

Conditions: Depression

Interventions: Behavioral: CALM Therapy

First Posted Date: 2021-04-21

Last Posted Date: 2025-02-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT04852302

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

Phase 1

Recruiting

Conditions: AL Amyloidosis

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Computed Tomography
Drug: Dexamethasone
Procedure: Echocardiography Test
Drug: Ixazomib Citrate
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Procedure: Transabdominal Ultrasound
Drug: Venetoclax
Procedure: X-Ray Imaging

First Posted Date: 2021-04-19

Last Posted Date: 2025-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT04847453

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center LAO, Duarte, California, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 14 locations

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

Phase 2

Recruiting

Conditions: Gastroesophageal Junction (GEJ) Cancers
Advanced HNSCC

Interventions: Drug: N-803
Drug: Pembrolizumab
Biological: PD-L1 t-haNK

First Posted Date: 2021-04-19

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT04847466

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies

Phase 1

Recruiting

Conditions: Peritoneal Mesothelioma
Ovarian Cancer
Gastrointestinal Cancer
Appendiceal Cancer
Peritoneal Carcinomatosis

Interventions: Procedure: Heated Intraperitonial Chemotherapy
Drug: Mitomycin C
Drug: Cisplatin
Drug: Oxaliplatin
Drug: 5-Fluorouracil
Drug: Doxorubicin
Drug: Sodium Thiosulfate

First Posted Date: 2021-04-15

Last Posted Date: 2025-05-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT04847063

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy

Phase 2

Completed

Conditions: Leukemia
Multiple Myeloma
Hematologic Malignancy
Lymphoma
Solid Tumor Malignancy

Interventions: Biological: Messenger ribonucleic acid (mRNA)-1273 Vaccine
Biological: Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster
Diagnostic Test: ECG
Other: Antibiotics
Other: Anti-viral agents
Other: Anti-fungal agent
Other: Anti-emetics

First Posted Date: 2021-04-15

Last Posted Date: 2024-08-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT04847050

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

Phase 1

Terminated

Conditions: Mesothelioma

Interventions: Biological: LMB-100
Drug: ipilimumab
Drug: Diphenhydramine
Drug: Famotidine
Drug: Acetaminophen
Drug: Dexamethasone
Procedure: Biopsy
Diagnostic Test: FDG-PET
Diagnostic Test: CT CAP
Diagnostic Test: MRI
Diagnostic Test: ECG
Diagnostic Test: Echocardiogram

First Posted Date: 2021-04-12

Last Posted Date: 2024-02-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2

Registration Number: NCT04840615

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Phase 2

Recruiting

Conditions: Lymphoplasmacytic Lymphoma
Waldenstrom Macroglobulinemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Ibrutinib
Procedure: Positron Emission Tomography
Biological: Rituximab
Drug: Venetoclax

First Posted Date: 2021-04-12

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 92

Registration Number: NCT04840602

Locations: 🇺🇸
Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States
🇺🇸
Grant Medical Center, Columbus, Ohio, United States
🇺🇸
Grady Memorial Hospital, Delaware, Ohio, United States

and more 107 locations

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Phase 1

Recruiting

Conditions: Refractory Ovarian Carcinoma
Metastatic Malignant Solid Neoplasm
Recurrent Platinum-Resistant Ovarian Carcinoma
Recurrent Malignant Solid Neoplasm

Interventions: Drug: BET Bromodomain Inhibitor ZEN-3694
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Biological: Ipilimumab
Biological: Nivolumab
Procedure: Positron Emission Tomography
Procedure: X-Ray Imaging

First Posted Date: 2021-04-12

Last Posted Date: 2025-05-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 66

Registration Number: NCT04840589

Locations: 🇺🇸
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
Montefiore Medical Center-Einstein Campus, Bronx, New York, United States

and more 4 locations

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Phase 1

Recruiting

Conditions: HRD Cancer
SCLC
Advanced Solid Tumors

Interventions: Drug: Berzosertib
Drug: Sacituzumab Govitecan

First Posted Date: 2021-04-01

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 120

Registration Number: NCT04826341

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Phase 2

Active, not recruiting

Conditions: Malignant Glioma
Glioblastoma
Gliosarcoma

Interventions: Drug: TMZ
Drug: ipilimumab 3mg/kg
Drug: Nivolumab
Drug: ipilimumab 1mg/kg

First Posted Date: 2021-03-26

Last Posted Date: 2025-04-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 47

Registration Number: NCT04817254

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy